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Division of Experimental Medicine, Department of Medicine, Centre for Haematology, Imperial College
London, London, United KingdomJohn Goldman’s inﬂuence on hematological practice
worldwide will be his ultimate professional legacy. Through
his passion to ﬁnd a cure for chronic myeloid leukemia
(CML), he was ﬁrst a pioneer in transplantation and more
recently helped bring the selective tyrosine kinase inhibitors
into clinical practice, thereby revolutionizing therapy of this
disease.
John joined Professor (later Sir) John Dacie’s hematology
department at the Hammersmith Hospital, home of the
Royal Postgraduate Medical School, in 1970. With a back-
ground training in radiotherapy and solid tumor oncology,
his initial interest was Hodgkin lymphoma, but he was soon
converted to CML and, together with Daniel Catovsky, joined
the Medical Research Council’s Leukaemia Unit under the
direction of David Galton. In the 1970s, the hematology
community was eagerly watching developments in Don
Thomas’ transplant group in Seattle. John was impress-
ed with Dean Buckner’s 1974 publication describing auto-
grafting in CML blast crisis using bone marrow collected in
the chronic phase. John had identiﬁed hematopoietic pro-
genitor cells in the blood of newly diagnosed persons with
CML and undertook the very ﬁrst transplants using their
chronic-phase blood cells as the graft when they entered
blast crisis, hoping to re-establish a second chronic phase.
Results were variable, but a few achieved prolonged
survivals. More fascinating was their initial recovery with
Philadelphia chromosomeenegative hemopoiesis, a ﬁnding
mirrored in Isabel Cunningham and Barney Clarkson’s work
using combination chemotherapy in blast crisis at Memorial
Sloan Kettering Cancer Center. This ability to restore normal
hemopoiesis in CML was the ﬁrst hint the disease might be
controllable with chemotherapy.1083-8791/$ e see front matter  2014 American Society for Blood and Marrow
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transplantation in CML, John moved logically to allografting
using sibling donors, gradually building the largest CML
transplant practice in Europe. A fruitful collaboration with
Herman Waldmann and Geoff Hale in Cambridge led to the
use of the Campath family of monoclonal antibodies (now
alemtuzamab) for T cell depletion. Although the eventual
ﬁnding of the increased risk of relapse (thus conﬁrming an
in vivo graft-versus-leukemia effect) was unexpected, John’s
group reported the results promptly and honestly and paved
the way to Hans Kolb’s effective use of additional donor
lymphocyte infusions for post-transplant relapse and the
development of reduced-intensity preparative regimens. An
additional bonus was John’s work with Nick Cross and Tim
Hughes to produce ﬁrst qualitative and later quantitative PCR
assays to detect relapse and monitor response to treatment.
The use of real-time quantitative PCR now underpins man-
agement of CML with tyrosine kinase inhibitors, and John
was actively working on international standardization of the
assay at the time of his death.
John’s expertise in transplantation and his strategic vision
in this discipline resulted in his extensive involvement in
national and international transplant societies. He was an
early member of European Group for Blood and Marrow
Transplantation (EBMT), becoming initially the Chair of the
Autologous and then Chronic Leukemia working parties. He
was elected President of EBMT from 1990 to 1994 and hosted
the 20th annual meeting in Harrogate, an event made
memorable not only for the level of scientiﬁc and clinical
debate but also for coping with mortar bombs disrupting
international travel at Heathrow, a freak snowstorm, and a
hurricane, which destroyed one of the venues. It is a long-
standing tradition that the outcome of all transplants in
Europe be reported to the EBMT, and John was tireless in
his promotion of this activity. He also insisted his depart-
mental results were sent to the International Bone Marrow
Transplant Registry (later Center for International Blood
and Marrow Transplant Research), thus supporting and
publishing many seminal papers in transplantation and
acting as Chairman from 1998 to 2000. Since that time he
supported emerging transplant societies throughout the
world, including being a founding member of the British
Society of Blood and Marrow Transplant.
In 1985, John performed the ﬁrst transplant for CML in
the United Kingdom using an HLA-identical volunteer un-
related donor. Mindful that such donors were in short
supply, he became increasingly involved with the UK-based
Anthony Nolan Register, supporting the enhanced recruit-
ment of individuals willing to altruistically donate their
blood or marrow cells for transplantation. On the retire-
ment of David James, John became the Scientiﬁc and Med-
ical Director of the Anthony Nolan Register, promoting theTransplantation.
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cellular therapies. He was an active supporter of the
development of donor registries, including cord blood cell
repositories, throughout the world, advising on their
establishment and best practices. His vision was behind the
creation of the World Marrow Donor Association, an orga-
nization that links donor registries across the world,
ensuring the same high standards for donor recruitment,
management, and cell collection are used globally, such that
cells travel freely across international borders. In 1987,
together with Robert Peter Gale, he established a new
journal, Bone Marrow Transplantation, serving as Editor-in-
Chief until his death.
Listening to Brian Druker’s ﬁrst oral presentation of
STI571 (later imatinib) at American Society of Hematology in
1996, John immediately realized the potential of these mol-
ecules as drugs that might one day replace interferon and
indeed transplantation in the management of CML. He
approached Brian on that day and became a lifelong sup-
porter and friend. Very few physicians have the privilege of
seeing in their lifetime one of their disease interests trans-
form from a fatal to a chronic easily controlled condition, but
this is exactly what happened to John, thanks to his tirelessefforts to promote development of the tyrosine kinase in-
hibitors. He loved Greek mythology and surely thought the
Gods were smiling on him.
No tribute to John could be complete without acknowl-
edgement of his humanity. Unfailingly polite, his easy charm
hid a formidable wit. Always willing to laugh at himself, he
was approachable and helpful and endeared himself to col-
leagues all over the world. John was an outstanding teacher,
remaining active at international meetings and on advisory
boards until a fewweeks before he died. But hemight be best
remembered and emulated for his devotion to his patients,
andmany an early transplant survivor will recall ﬁnding John
at their bedside in the early hours of the morning, checking
on progress and reassuring the sleepless. He was the
consummate physician, combining outstanding clinical skills
with never-ending intellectual curiosity, and hewill be much
missed by all those who encountered him. He left a strong
department at Hammersmith Hospital, now headed by his
protégé, Professor Jane Apperley.
John Michael Goldman died on December 24th after a
brief illness. He is survived by his 3 children, Lucy, Cassandra,
and Jasper, and 4 grandchildren. He is likely with the Gods
who so loved him.
